Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) had its price objective cut by equities research analysts at HC Wainwright from $75.00 to $70.00 in a research note issued on Tuesday,Benzinga ...

H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is ...

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago. These ...

Reports Q4 revenue $629k, consensus $433.33k. “2024 was a pivotal year for the company, paving the way for the future of Aligos,” stated ...

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best ...

Rostermania rages on in North America with many of Apex's biggest names finding themselves new homes. With year five of the ...

ALIGOS THERAPEUTICS ($ALGS) is expected to release its quarterly earnings data on Monday, March 10th before market open, per Finnhub. Analysts are expecting revenue ...

Esports athlete Reps to leave TSM after nearly six years of professional play with the team, but shares that he's not quitting Apex Legends.